Dear Jethro. The attached paper shows and compares different ways of quantifying angiogenesis in scaffolds and may be of some help. Best Regards. Deon

You can seed a primary cell line such as HMVEC in your scaffold to look for survival or proliferation using flow cytometry or cytohistochemistry. Alternatively, if you want to use a quick in vivo method, I suggest the DIVAA kit, we have had moderate success assessing the angiogenic capacity of novel bioscaffolds or conditioned media. 

Please see:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2517524/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071699/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646220/

https://www.ncbi.nlm.nih.gov/pubmed/12507958

http://www.bdbiosciences.com/documents/webinar_2010_05_angiogenesis.pdf

https://www.sri.com/sites/default/files/brochures/evaluatingcompoundsaffectingangiogenesis.pdf

Wishes

Rakesh

By doing immunohistochemistry as such:

The microvessel density (MVD) can be assessed at low power (magnification, ×40) then microvessel counting is done on 10 representative high power fields (magnification, ×400) selected from the highest vascular density areas (hot spots). Vessels with a clearly defined lumen (but not single cells) are taken into account for microvessel counting. The the average microvessel counts are obtained from these 10 fields. Then you can adopt a two-scale grading system of MVD (low and high) using one cut-off point (the median microvessel count). Tumors with less than cut-off pointare considered as low MVD while those with equal or higher values (re considered as high MVD.

the microvessels can be visualized by immunohistochemical endothelial markers like CD34 or CD31.